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Abstract WTl was isolated as a tumor suppressor gene of 
Wilms tumor. However, high expression of WTl correlates with 
poor prognosis in acute leukemia. In addition suppression of 
WTl expression by WTl anti-sense oligonucleotide inhibits 
proliferation of leukemia cells, suggesting that WTl is important 
for their proliferation. To further elucidate the biological 
significance of WTl in leukemic cell growth, we overexpressed 
exogenous WTl in murine M l myeloblastic leukemia cells using 
the isopropyl-ß-D-thiogalactoside (IPTG)-controlled expression 
system. We found that induction of one splicing variant of WTl 
\WTl-17AA(+)-KTS('-)] in M l cells induces cell cycle arrest 
and apoptotic cell death. These results suggest that the role of 
WTl is different depending on the type of leukemia cell in which 
it is expressed. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Wilms tumor is a childhood kidney tumor that arises from 
metanephric blastema and is associated with inactivation of 
both alleles of the WTl gene [1-3]. WTl was isolated by the 
positional cloning technique and shown to be mutated in 
about 10% of sporadic Wilms tumors [2-6]. The WTl gene 
encodes a transcription factor with four carboxyl Cys 2 -His 2 
zinc fingers and two alternative splicing events, referred to as 
splices I and II, produce four isoforms of the protein [2,7]. 
Splice I results in the insertion of 17 amino acids upstream of 
the zinc finger domain and enhances the transcriptional activ-
ity of the protein [8]. Splice II occurs within the zinc finger 
domain, inserting three amino acids (Lys-Thr-Ser ; KTS) be-
tween the third and fourth zinc fingers and changes the D N A 
binding specificity of the protein [9,10]. The W T l protein 
without splice II specifically binds to the EGR-1 consensus 
sequence, to the (TCC)n motif and to the W T E motif 
[9,11,12]. By binding to these sites, the latter W T l isoform 
can either repress or activate transcription from promoters 
of genes encoding insulin-like growth factor (IGF)-2, plate-
let-derived growth factor A (PDGF-A) , insulin-like growth 
factor-1 receptor ( IGF1R), epidermal growth factor receptor 
(EGFR) , Bcl-2, c-Myc [13-16]. 
The WTl gene is expressed in various tissues including fetal 
kidney, testis, ovary and supportive structures of mesoderm 
origin [2,3,17-19]. Analysis of mice with homozygous deletion 
of the WTl gene has demonstrated the crucial role of this 
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gene in early urogenital development [20]. The expression of 
WTl is also observed in hematopoietic tissues such as CD34+ 
bone marrow cells and immature leukemia cells [21-23]. In 
some leukemia cell lines, down-regulation of the WTl gene 
occurs during differentiation along the myeloid and erythroid 
lineage pathways [24,25], and WTl antisense oligonucleotides 
inhibit the proliferation of these cells [26]. Interestingly, there 
is a correlation between high WTl expression and poor prog-
nosis in acute leukemia [22]. These findings suggest that WTl 
is important for the malignant proliferation of leukemic cells. 
In this study, we tried to further establish the biological 
significance of WTl in leukemic cell growth using M l myelo-
blastic leukemia cells and the IPTG-inducible LacSwitch ex-
pression system to regulate expression of W T l . M l cells are 
well known to be induced to differentiate in response to IL-6 
[27,28]. We therefore imagined that exogenous expression of 
W T l in M l cells, which express barely detectable levels of 
W T l , may induce enhanced proliferation and resistance to 
the induction of differentiation. However, we unexpectedly 
found that the expression of exogenous W T l containing splice 
I but not splice II in M l cells induces cell cycle arrest and 
apoptotic cell death. 
2. Materials and methods 
2.1. Cell culture 
Murine Ml myeloblastic leukemia cells were maintained in Eagle's 
minimal essential medium supplemented with 10% heat-inactivated 
fetal bovine serum and twice the standard concentration of amino 
acids and vitamins. Cells were transfected with the WTl expression 
plasmids by electroporation. Drug-resistant colonies were selected by 
growth in G418 (450 ug/ml) or hygromycin (80 ug/ml). To generate 
growth curves, cells were seeded in 6 cm dishes at 5 X 104 cells/plate in 
the presence or absence of 5 mM IPTG and duplicate plates were 
counted. Viable cell numbers were determined by trypan blue exclu-
sion and counted in a hemacytometer. 
2.2. Plasmid construction and electroporation 
The LacSwitch-inducible mammalian expression system (STRATA-
GENE) was used for inducible expression of WTl. cDNAs encoding 
various full-length human WTl variants were cloned into pOPRSVI, 
an expression vector containing both RSV and lac operator sequences 
in its promoter. The WTl constructs contained either alternative 
splice I alone or alternative splices I and II. 
For electroporation, 107 cells were washed twice with PBS and 
resuspended in 0.8 ml of PBS containing 20 ug of p3'SS, a eukaryotic 
lac-repressor-expressing vector, and 20 ug of each pOPRSVI-WTl 
construct and electroporated at 300 V, 960 uF using a Bio-Rad 
Gene pluser. Geneticin and hygromycin-resistant colonies were iso-
lated and screened for WTl expression by culturing in 5 mM IPTG 
followed by Western blot analysis. 
2.3. Western blotting 
Cell extracts for Western analysis were prepared from sub-confluent 
cultures, and 100 ug of protein from each cell line was analyzed by 
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polyacrylamide gel electrophoresis. After transfer to an Immobilon-P 
membrane (Millipore, Bedford, MA), the blot was probed with mono-
clonal anti-WTl antibody. The protein was detected using anti-mouse 
IgG secondary antibody conjugated with alkaline phosphatase (Prom-
ega, Madison, WI). The anti-WTl antibody recognizes both human 
and murine WTl. 
2.4. DNA fragment assay 
Cells were seeded at 4X105 cells per 6 cm dish, cultured in the 
presence or absence of 5 mM IPTG and harvested after 72 h. DNA 
was isolated and electrophoresed on a 2% agarose gel as described by 
Smith et al. [29]. 
2.5. Flow cytometric analysis 
Cells (5 X 105 cells/dish) cultured in the presence or absence of 5 mM 
IPTG were harvested, washed, fixed and stained with propidium 
iodide. Flow cytometric analysis was performed on a FACScan (Bee-
ton Dickinson), using a ModFit LT. 
3. Results 
3.1. Inducible expression of exogenous WTl in stably 
transfected Ml cells 
To establish stable cell lines that express the exogenous 
WTl gene, we used an inducible expression system controlled 
by the lac-repressor. In this system, expression of the lac-re-
pressor allows strict regulation of a promoter containing a lac 
operator. When WTl containing splices I and II [WT1-
17AA(+)-KTS(+)] or WTl containing splice I but not splice 
II [WTl-17AA(+)-KTS(-)] was transfected into murine Ml 
myeloblastic leukemia cells, we obtained several cell lines in 
which exogenous WTl could be inducibly expressed in re-
sponse to IPTG. Western blot analysis using monoclonal 
anti-WTl antibody showed that WTl expression is undetect-
able in these cells in the absence of IPTG but increases after 
addition of IPTG (Fig. la). The induced protein was detected 
as early as 3 h after addition of IPTG (Fig. lb). 
3.2. Growth of cell lines expressing exogenous WTl 
To examine the effect of expression of WTl on the growth 
of Ml cells, MD2 and MD8 cells, which inducibly express 
WTl-17AA(+)-KTS(-), and MB21 and MB27 cells, which 
inducibly express WTl-17AA(+)-KTS(+), were cultured in 
the presence or absence of IPTG and the number of viable 
cells were counted at various time points. The growth rate of 
MD8 (Fig. 2) and MD2 (data not shown) cultured in the 
absence of IPTG was virtually the same as that of the 
mock-transfected cells. However, in the presence of IPTG, 
the number of viable MD8 and MD2 cells increased for 72 
h and started to decrease thereafter due to growth arrest and 
cell death. In contrast, the growth rate of MB27 (Fig. 2) and 
MB21 (data not shown) cultured in the presence of IPTG was 
the same as that of the mock-transfected cells. The effect of 
Fig. 1. a: Inducible expression of exogenous WTl in Ml-derived cell lines that had been transfected with WTl-17AA(+)-KTS(+) (MB21 and 
MB27) or WTl-17AA(+)-KTS(—) (MD2 and MD8). Lysates from Ml transfectants grown in the presence or absence of IPTG for 24 h were 
subjected to Western blot analysis using anti-WTl monoclonal antibody, b: Time course of WTl induction. MD8 cells were cultured in the 
presence of IPTG and harvested for Western blot analysis at the indicated time points. The arrow indicates WTl. 
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Fig. 2. Growth curves of cell lines expressing exogenous WTl. Cells were seeded in 6 cm dishes at 5.0X 104 cells/plate and cultured for 6 days. 
Mock-transfected and MB27 cells were cultured in the presence of IPTG. MD8 cells was cultured in the presence or absence of IPTG. Viable 
cell number was determined by trypan blue exclusion at the indicated times. 
WTl-17AA(+)-KTS(-) was observed regardless of the pres-
ence or absence of IL-6 in the medium (data not shown). On 
the other hand, WTl-17AA(+)-KTS(+) did not show the de-
tectable effect on IL-6-induced differentiation of Ml cells 
(data not shown). 
3.3. Cell cycle analysis of Ml cells expressing exogenous WTl 
We previously demonstrated that overexpression of WTl 
blocks cell cycle progression from the Gl to S phase in mouse 
fibroblast cells [30]. To test whether expression of WT1-
17AA(+)-KTS(—) in Ml cells induces cell cycle arrest at a 
specific point, MD8 cells were subjected to cell cycle analysis 
after addition of IPTG. The relative percentage of cells in the 
Gl phase slowly increased from 35% up to 60% until 120 h 
after addition of IPTG (Table 1). However, in the absence of 
IPTG, MD8 cells exhibited little change in the percentage of 
Table 1 
Cell cycle analysis of WTl-17A.A(+)-KTS(-)-expressing cells 
IPTG(-) 
IPTG(+) 
Cell cycle distribution (%) 
Oh 
36.5 
49.8 
13.7 
35.4 
49.2 
15.4 
24 h 
37.8 
51.2 
11.0 
40.4 
48.8 
10.8 
48 h 
36.6 
49.3 
14.1 
45.6 
40.8 
13.6 
72 h 
35.2 
52.4 
12.4 
53.7 
35.5 
10.8 
96 h 
36.5 
51.2 
12.3 
56.7 
32.7 
10.6 
120 h 
39.5 
49.4 
11.1 
60.0 
29.8 
10.2 
Gl 
S 
G2/M 
Gl 
S 
G2/M 
Percentage of MD8 cells in each cell cycle phase in the presence or 
absence of IPTG are shown (mean of two experiments). 
cells in the Gl phase. MD2 cells also showed a quite similar 
cell cycle distribution pattern in response to IPTG (data not 
shown). These results suggest that expression of WT1-
17AA(+)-KTS(-) in Ml cells induces Gl arrest. 
3.4. Death of WTl-expressing Ml cells occurs by apoptosis 
To examine whether WTl-induced cell death is caused by 
apoptosis or not, genomic DNA was prepared from MD8 and 
MB27 cells cultured in the presence or absence of IPTG. As 
shown in Fig. 3, genomic DNA from MD8 cells was frag-
mented into the typical nucleosome spacing ladder at 72 h 
after addition of IPTG. On the other hand, genomic DNA 
from MB27 and mock-transfected cells showed little or no 
indication of such DNA fragmentation. Similarly, MD2 but 
not MB21 showed DNA fragmentation when treated with 
IPTG (data not shown). These results suggest that expression 
of WTl-17AA(+)-KTS(-) induces apoptotic cell death. 
4. Discussion 
WTl is highly expressed in many types of leukemia cells 
and high expression of WTl correlates with poor prognosis in 
acute leukemia [21,22]. Furthermore, abrogation of WTl ex-
pression using antisense oligonucleotide inhibits proliferation 
of K562 cells and fresh leukemic cells from patients with 
AML and CML blast crisis, suggesting that WTl is important 
for the proliferation of leukemic cells [26]. However, in the 
present study we show that overexpression of WT1-17AA(+)-
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Fig. 3. DNA fragmentation assay. Cells were seeded in 6 cm dishes 
at 5.0X104 cells/plate and harvested after 72 h. Mock-transfected 
and MB27 cells were cultured in the presence of IPTG. MD8 cells 
were cultured in the presence or absence of IPTG. DNA was iso-
lated and electrophoresed on a 2% agarose gel. 
KTS(—) induces Gl arrest and apoptotic cell death in Ml 
myeloblastic leukemia cells. Thus the role of WT1 is different 
depending on the type of leukemia cell in which it is ex-
pressed. In this regard, it is interesting to note that WT1 
shows different transcriptional activity depending on the 
type of cell. For example, WT1 suppresses transcription 
from the EGR1 promoter in NIH 3T3 and 293 cells in tran-
sient transcription assays [31], but activates it in Saos-2 cells 
and in cells expressing mutant p53 [32]. Hence, depending on 
the type of leukemia cell WT1 may differently regulate the 
transcription of genes which regulate cell growth and apop-
totic cell death. 
In cells derived from other tissues, WT1 has been shown to 
have a potential to induce growth arrest and apoptosis. Over-
expression of WT1 blocks the Gl-S transition of NIH 3T3 
cells [30], while constitutive expression of WT1 in F9 embry-
onal carcinoma cells induces apoptosis in response to retinoic 
acid [33]. WT1 also induces apoptotic cell death when ectopi-
cally expressed in osteosarcoma cell lines [15]. These findings 
also indicate that the effect of WT1 is different depending on 
the background of cells in which it is expressed. 
While exogenous expression of WTl-17AA(+)-KTS(—) in-
duced Gl arrest and apoptotic cell death, WT1-17AA(+)-
KTS(+) did not show this activity. This difference may be 
partly explained by difference in transcriptional regulator ac-
tivity of the two isoforms. The presence of K.TS between zinc 
finger 3 and 4 changes the DNA binding specificity of the 
protein [12,34], and only WTl-17AA(+)-KTS(-) may be 
able to bind promoters of target genes critical for Gl arrest 
and apoptosis. In addition, it has recently been reported that 
the nuclear localization pattern of WT1-KTS(+) is different 
from that of WT1-KTS(—), and the former is found associ-
ated with splicing factors, suggesting that WT1-KTS(+) is 
involved in RNA metabolism [35]. Thus our data indicates 
that the putative post-transcriptional processing activity of 
WT1 is not important for the induction of Gl arrest and 
apoptosis. 
WT1 has been reported to repress transcription of the bcl-2 
and IGF1R genes, which play important roles in the prolifer-
ation and apoptosis of hematopoietic cells [36-38]. However, 
our preliminary experiments show that the expression of these 
genes is not significantly repressed by WT1 in Ml cells (data 
not shown). Also, although WT1 is reported to induce apop-
tosis in osteosarcoma cell lines by repressing transcription of 
the EGF receptor [15], Ml cells do not express the EGF 
receptor. In addition, wild-type p53 is not expressed in Ml 
cells. Thus, WTl-induced apoptosis observed in this study is 
independent of the EGF receptor and p53. The target genes 
important for the WT1-mediated induction of Gl arrest and 
apoptosis remain to be elucidated. 
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